NTRA Q3 2023 Earnings — Natera, Inc. Revenue & Financial Results | Market Cap Arena

NTRANatera, Inc.

$29B

Q3 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$268M+27.4% YoY

Gross Profit

$121M45.1% margin

Operating Income

-$111M-41.4% margin

Net Income

-$109M-40.6% margin

EPS (Diluted)

$-0.95

QoQ Revenue Growth

+2.6%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$39M

Stock-Based Comp.

$58M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$662M

Stockholders' Equity

$785M

Cash & Equivalents

$669M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$268M	$211M	+27.4%
Gross Profit	$121M	$94M	+28.5%
Operating Income	-$111M	-$119M	+6.8%
Net Income	-$109M	-$121M	+10.2%

Revenue Segments

Product

$265M92%

Oncology products

$19M7%

Licensing and other

$3M1%

Geographic Segments

United States

$260M97%

Europe, Middle East, India, Africa

$5M2%

Asia Pacific and Other

$2M1%

Americas, excluding U.S.

$1M0%